Kopran Ltd
Kopran Ltd Q3 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY 2025-26 Revenue from Operations: Rs. Q3 FY 2025-26 Financials: - EBITDA: Rs.
From Kopran Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY 2025-26 Revenue from Operations: Rs. 19,428 lakhs (Page 5)
- Q3 FY 2024-25 Revenue from Operations: Rs. 16,624 lakhs (Page 5)
- Year-on-year revenue increase: Rs. 2,804 lakhs (~16.87% increase)
- Formulations Q3 FY 2025-26 revenue: Rs. 9,231 lakhs (Page 9)
- Formulations Q3 FY 2024-25 revenue not explicitly stated for direct YoY comparison.
- APIs Q3 FY 2025-26 revenue: Rs. 10,005 lakhs (Page 8)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Strategic focus on capacity expansion mentioned under "STRATEGIC IMPERATIVES" (Page 15) without specific amounts or timelines.
- API and R&D facility located at Panoli (Gujarat) noted, implying operational status (Page 15).
- No explicit capex amounts or detailed timelines related to new plants or projects are provided in the presentation.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q3 FY26)
Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q3 FY26 investor presentation — and how it ranks aga
- Shree Ganesh Remedies Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank
- Anuh Pharma Ltd (Q3 FY26)
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw
- Bharat Parenterals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). Key investor presentation takeaways from Bharat
Frequently Asked Questions
What were Kopran Ltd Q3 FY26 results?
Q3 FY 2025-26 Revenue from Operations: Rs. Q3 FY 2025-26 Financials: - EBITDA: Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Strategic focus on capacity expansion mentioned under "STRATEGIC IMPERATIVES" (Page 15) without specific amounts or timelines.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.